Premium
Investigation of early antibiotic use in pediatric patients with acute respiratory infections by high‐performance liquid chromatography
Author(s) -
Van Toi Pham,
Doan Khanh V.,
Minh Ngo Ngọc Quang,
Phuong Pham Nguyen,
Jong Menno D.,
Doorn H. Rogier,
Pouplin Thomas
Publication year - 2020
Publication title -
biomedical chromatography
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.4
H-Index - 65
eISSN - 1099-0801
pISSN - 0269-3879
DOI - 10.1002/bmc.4699
Subject(s) - cefixime , cefuroxime , cefadroxil , cefaclor , chromatography , cefdinir , chemistry , amoxicillin , high performance liquid chromatography , cephalosporin , antibiotics , biochemistry
In this study, we developed and validated two reliable high‐performance liquid chromatography (HPLC) methods for the qualitative detection of six oral β ‐lactams, which are commonly used in pediatric patients with acute respiratory infections (ARIs). Two distinct reverse‐phase chromatographic separations of six β ‐lactams were obtained. Four β ‐lactams (cefadroxil, cephalexin, cefaclor and cefixime) in urine were separated using a gradient program with a mobile phase consisting of K 2 HPO 4 buffer (20 m m , pH 2.8) and acetonitrile on a LichroCART 250 × 4.6 mm, Purospher STAR C 18 end‐capped (5 μm) column. Two remained β ‐lactams (amoxicillin and cefuroxime) were analyzed using a gradient elution with the mobile phase containing K 2 HPO 4 buffer (20 m m , pH 3.0) and acetonitrile on a LichroCart ® Purospher Star C 8 end‐capped column (5 μm, 125 × 4.6 mm). Good linearity within the range of 0.3–30 μg/ml for cefadroxil, cephalexin, cefaclor and cefixime, and 0.2–20 μg/ml for amoxicillin and cefuroxime, was attained. The precisions were <14%. The accuracies ranged from 85.87 to 102.8%. The two validated methods were then applied to determine these six antibiotics in 553 urine samples of pediatric patients with ARIs. As a result, 32.2% were positive with one or more of six tested β ‐lactams. Cefixime was the most commonly detected agent, accounting for 9.8% of enrolled patients.